// App-Quantinova.ai

TPS2110 : GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of PF-299804 (dacomitinib), a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation.

Researchers

Presenter

  • Juan Manuel Seplveda

Principal Investigators

  • M. Angeles Vaz

  • Aurelio Hernandez-Lain

  • Maria Martinez Garcia

  • Pedro Perez Segura

  • Manuel Benavides

  • Carmen Bala

  • Ramos Ana

  • Oscar Gallego

  • Gaspar Reynes

  • Maria Victoria Bols

  • Raquel Luque

  • M. Quindos

Medical Centers

  • Hospital De Sant Pau, Barcelona, Spain

  • Oncologia Medica. Hospital del Mar, Barcelona, Spain

  • Instituto de Salud Carlos III, Majadahonda, Spain

  • Hospital Universitari Germans Trias i Pujol, Badalona, Spain

  • Hospital Clinico Universitario San Carlos, Madrid, Spain

  • Hospital Ramon y Cajal, Madrid, SpainC. H. Juan Canalejo, A Coruna, SpainMedical Oncology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain

  • Hospital Universitario La Fe de Valencia, Valencia, Spain

  • Hospital Carlos Haya, Malaga, Spain

  • Pfizer Spain, Madrid, Spain

  • 12 de Octubre Universitary Hospital, Madrid, Spain

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Catalan Institute of Oncology, Germans Trias, Barcelona, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Glioblastoma

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • Epidermal growth factor receptor

Drug/Treatment

  • CB-7598

  • Temozolomide

  • Bevacizumab

  • dacomitinib

  • PF-299804

  • EGFRvIII

  • Lercanidipine hydrochloride

Outcome

  • Unknown

Study Design

  • open label

  • randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • Pfizer

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved